Towards freedom from disease? Episode 2

This webinar will focus on the short- and long-term safety data and mechanisms of action of new drugs and on management decisions for treating psoriatic arthritis. We invite rheumatologists and dermatologists from around the world to tune in for the presentations given by the esteemed faculty and to interact with them during the interactive segments of the programme.

We hope you can join us during this live, interactive session. If you are unable to attend the live broadcast, you will be able to watch the on-demand version once it is available.

Learning objectives

After this webinar, participants should be able to:

• Relate IL-23 pathophysiology to the different domains of psoriatic arthritis
• Describe the effects of IL-23 inhibitors on long-term efficacy and safety
• Reflect on how comorbidities, disease severity, and drug safety could drive management decisions in 2021

Faculty

• Iain McInnes
• Kristian Reich
• Carlo Selmi

Programme (all times in CET)

17:30–17:35 Welcome
Iain McInnes

17:35–17:50 IL-23 pathophysiology through the PsA domains
Carlo Selmi

17:50–18:05 Lessons from dermatology: IL-23 in disease modification and long-term safety
Kristian Reich

18:05–18:25 The forces driving management decisions in 2021 – interactive panel discussion and Q&A
Kristian Reich and Carlo Selmi, moderated by Iain McInnes

18:25–18:30 Summary and close
Kristian Reich